Authors
Gurubhej Singh Thakral
Abstract
Cardiovascular diseases (CDV) and cancer represent the foremost reason of morbidity and death globally. Prevention of these diseases plays vital role for decreasing the incidence of following conditions. Aspirin has a well-accepted role in prevention of cardiovascular diseases. In recent years some trials also suggested preventive effect of aspirin for various types of cancer. In developing countries aspirin is inexpensive and widely acceptable. The anticlotting effect of aspirin is helpful for main prevention for the reason that it possibly reduces the growth of blood clots that form as a result of decreased flow of blood at atherosclerotic plaques, thus reducing hypoxic harm to brain and heart tissue. The role of aspirin for cancer and cardiovascular diseases remain to be a cause of maximum discussion, with mainly international recommendations providing contradictory endorsements. Here, we evaluate the evidence in approval as well as in contradiction of aspirin therapy in prime prevention dependent on the evidence gathered with, including present linking data of aspirin connection with cancer protection. Keywords: Aspirin, Primary Prevention, Diseases.
Introduction
At the end of 19th century a drug was imitative from salicylic acid and has been used widely over the years as an analgesic, anti-inflammatory, and antipyretic agent. Aspirin or acetylsalicylic acid, is the acetylated version of the natural product and the aim is to improve the tolerability of the drug. This drug is considered as most widely used for the purpose of medication. According to Agency for Healthcare Research and Quality (AHRQ) in 2007, stated that in United States around 20% of adults consumed aspirin regularly or every other day. This number is increasing to approximately 50% in the age range of 65 and more.
In certain subclasses of patients, e.g. patients having peripheral vascular disease, diabetes mellitus where the specific profits have not been fully elucidated use of aspirin. The secondary prevention benefits of aspirin treatment seems to outweigh the risks. In case of fit individuals where the threat of thrombotic cardiac event, the role of primary prevention of aspirin is not clear. In primary prevention, numerous present guidelines mention the use of aspirin but do not fully reflect the danger of bleeding.
References
M, Xie, et al. “Aspirin for Primary Prevention of Cardiovascular Events in People with Diabetes: Meta-Analysis of Randomised Controlled Trials.” Clinical Governance: An International Journal, vol. 15, no. 2, 2010,
Cleland, J. G. F. “Is Aspirin Useful in Primary Prevention?” European Heart Journal, vol. 34, no. 44, Jan. 2013, pp. 3412–3418.
Dai, Yuxiang, and Junbo Ge. “Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease.” Thrombosis, vol. 2012, 2012, pp. 1–7.
Ittaman, Sunitha V., et al. “The Role of Aspirin in the Prevention of Cardiovascular Disease” Clinical Medicine & Research, Dec. 2014, Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC4317158/.
Kittisak Sawanyawisuth, et al. “Aspirin Therapy as Primary Prevention in Hypertensive Patients at Srinagarind Hospital.” The Medical Association of Thailand = Chotmaihet Thangphaet, Jan. 2006, pp. 1797–1801.
Kwok, Chun Shing, and Yoon Loke. “Critical Overview on the Benefits and Harms of Aspirin.” Pharmaceuticals, vol. 3, no. 5, 2010, pp. 1491–1506.
Lei, Hong, et al. “The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: A Meta-Analysis of Randomized Trials.” Frontiers in Pharmacology, vol. 7, 2016.
N. Nansseu, Jobert Richie, and Jean Jacques N. Noubiap. “Aspirin for Primary Prevention of Cardiovascular Disease.” Thrombosis Journal, 4 Dec. 2015.
Sutcliffe, Paul, et al. Aspirin in Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Review of the Balance of Evidence from Reviews of Randomized Trials. U.S. National Library of Medicine, 2013, Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC3855368/.
Torres, Yaniel Castro, et al. “Aspirin for Primary Prevention of Cardiovascular Diseases: Current Concepts, Unanswered Questions and Future Directions.” Hellenic Journal of Cardiology, 13 Oct. 2015, pp. 461–474.
How to cite this article?
| APA Style | Thakral, G. S. (2019). Study of Aspirin in Primary Prevention. Academic Journal of Chemical Sciences, 1(1), 15-18. |
| Chicago Style | |
| MLA Style | |
| DOI | |
| URL |